ProApolipoprotein A1: A serum marker of brain metastases in lung cancer patients

Cancer

Volumn 112, Issue 6, 2008, Pages 1313-1324

  Marchi, Nicola ^a   Mazzone, Peter ^a   Fazio, Vincent ^a   Mekhail, Tarek ^a   Masaryk, Thomas ^a   Janigro, Damir ^a,b  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Apolipoprotein A1; Central nervous system; Cerebrovascular disease; Lung cancer; Metastatic brain cancer; ProApolipoprotein

Indexed keywords

APOLIPOPROTEIN A1; HAPTOGLOBIN; PREALBUMIN; PROAPOLIPOPROTEIN A1; PROTEIN S100B; TRANSFERRIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN DISEASE; BRAIN ISCHEMIA; BRAIN METASTASIS; CANCER DIAGNOSIS; CEREBROVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; SERUM; UPREGULATION;

ADENOCARCINOMA; AMINO ACID SEQUENCE; APOLIPOPROTEIN A-I; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CEREBROVASCULAR DISORDERS; CHRONIC DISEASE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HAPTOGLOBINS; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; NERVE GROWTH FACTORS; PREALBUMIN; S100 PROTEINS; TRANSFERRIN; TUMOR MARKERS, BIOLOGICAL;

EID: 41149133332     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23314     Document Type: Article

References (39)

1. Peacock KH, Lesser GJ. Current therapeutic approaches in patients with brain metastases. Curr Treat Options Oncol. 2006;7:479-489.
2. Higer HP, Pedrosa P, Schuth M. MR imaging of cerebral tumors: state of the art and work in progress. Neurosurg Rev. 1989;12:91-106.
3. Soffietti R, Ruda R, Mutani R. Management of brain metastases. J Neurol. 2002;249:1357-1369.
4. Kanner AA, Marchi N, Fazio V et al. Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer. 2003;97:2806-2813. Erratum in: Cancer. 2006;107:2314. Ayumar, Barbara [corrected to Aumayr, Barbara].
5. Vogelbaum MA, Masaryk T, Mazzone P, et al. S100beta as a predictor of brain metastases: brain versus cerebrovascular damage. Cancer. 2005;104:817-824.
6. Marchi N, Fazio V, Cucullo L, et al. Serum transthyretin as a possible marker of blood-to-CSF barrier disruption. J Neurosci. 2003;23:1949-1955.
7. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging. 1999;10:254-259.
8. Fazio V, Bhudia SK, Marchi N, Aumayr B, Janigro D. Peripheral detection of S100β during cardiothoracic surgery: what are we really measuring? Ann Thoracic Surg. 2004;78:46-52.
9. Kapural M, Krizanac-Bengez L, Barnett G, et al. Serum S100β as a possible marker of blood-brain barrier disruption. Brain Res. 2002;940:102-104.
10. Marchi N, Rasmussen P, Kapural M, et al. Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci. 2003;21:109-121.
11. Buccoliero AM, Caldarella A, Noccioli B, Fiorini P, Taddei A, Taddei GL. Brain heterotopia in pharyngeal region. A morphological and immunohistochemical study. Pathol Res Pract. 2002;198:59-63.
12. Dyck RH, Van Eldik LJ, Cynader MS. Immunohistochemical localization of the S100β protein in postnatal cat visual cortex: spatial and temporal patterns of expression in cortical and subcortical glia. Brain Res Dev Brain Res. 1993;72:181-192.
13. Mercier F, Hatton GI. Immunocytochemical basis for a meningeo-glial network. J Comp Neurol. 2000;420:445-465.
14. Jonsson H, Johnsson P, Alling C, Backstrom M, Bergh C, Blomquist S. S100β after coronary artery surgery: release pattern, source of contamination, and relation to neuropsychological outcome. Ann Thorac Surg. 1999;68:2202-2228.
15. Mrak RE, Flanigan S, Collins CL. Malignant acoustic schwannoma. Arch Pathol Lab Med. 1994;118:557-561.
16. Rickmann M, Wolff JR. Modifications of S100-protein immunoreactivity in rat brain induced by tissue preparation. Histochem Cell Biol. 1995;103:135-145.
17. Georgiadis D, Berger A, Kowatschev E, et al. Predictive value of S100β and neuron-specific enolase serum levels for adverse neurologic outcome after cardiac surgery. J Thorac Cardiovasc Surg. 2000;119:138-147.
18. Janigro D, Marchi N. Markers of blood barrier disruption and methods of using same. Patent No. 7,144,708. 12-5-2006.
19. Fish RG, Gill TS, Adams M, Faqeera F, Kerby I. Changes in serum acute phase proteins in ovarian cancer patients receiving cis-diamminedichloroplatinum (CDDP) infusion therapy. Clin Biochem. 1984;17:39-41.
20. Fish RG, Gill TS, Adams M, Kerby I. Serum haptoglobin and alpha 1-acid glycoprotein as indicators of the effectiveness of cis-diamminedichloroplatinum (CDDP) in ovarian cancer patients - a preliminary report. Eur J Cancer Clin Oncol. 1984;20:625-630.
21. Mueller WK, Handschumacher R, Wade ME. Serum haptoglobin in patients with ovarian malignancies. Obstet Gynecol. 1971;38:427-435.
22. Diamandis EP, van der Merwe DE. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res. 2005;11:963-965.
23. Biberthaler P, Mussack T, Wiedemann E, et al. Rapid identification of high-risk patients after minor head trauma (MHT) by assessment of S100β: ascertainment of a cut-off level. Eur J Med Res. 2002;7:164-170.
24. Biberthaler P, Mussack T, Wiedemann E, et al. Elevated serum levels of S100β reflect the extent of brain injury in alcohol intoxicated patients after mild head trauma. Shock. 2001;16:97-101.
25. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.
26. Law SW, Brewer HB Jr. Nucleotide sequence and the encoded amino acids of human apolipoprotein A-I mRNA. Proc Natl Acad Sci U S A. 1984;81:66-70.
27. Law SW, Gray G, Brewer HB Jr, Sakaguchi AY, Naylor SL. Human apolipoprotein A-I and C-III genes reside in the p11-q13 region of chromosome 11. Biochem Biophys Res Commun. 1984;118:934-942.
28. Brouillette CG, Anantharamaiah GM, Engler JA, Borhani DW. Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim Biophys Acta. 2001;1531:4-46.
29. Contiero E, Ferrari R, Vaselli GM, Folin M. Apolipoprotein AI isoforms in serum determined by isoelectric focusing and immunoblotting. Electrophoresis. 1997;18:122-126.
30. Bojanovski D, Gregg RE, Ghiselli G, Schaefer EI, Light JA, Brewer HB Jr. Human apolipoprotein A-I isoprotein metabolism: proapoA-I conversion to mature apoA-I. J Lipid Res. 1985;26:185-193.
31. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 2005;5:4589-4596.
32. Ai J, Tan Y, Ying W, et al. Proteome analysis of hepatocellular carcinoma by laser capture microdissection. Proteomics. 2006;6:538-546.
33. Huang HL, Stasyk T, Morandell S, et al. Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis. 2006;27:1641-1650.
34. Engwegen JY, Helgason HH, Cats A, et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol. 2006;12:1536-1544.
35. Goufman EI, Moshkovskii SA, Tikhonova OV et al. Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions. Biochemistry (Mosc). 2006;71:354-360.
36. Moore LE, Fung ET, McGuire M, et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev. 2006;15:1641-1666.
37. Ehmann M, Felix K, Hartmann D, et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas. 2007;34:205-214.
38. Mikuriya K, Kuramitsu Y, Ryozawa S, et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by 2-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol. 2007;30:849-855.
39. Pyle LE, Sviridov D, Fidge NH. Characterization of the maturation of human pro-apolipoprotein A-I in an in vitro model. Biochemistry. 2001;40:3101-3118.